• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)

    1/23/24 9:35:14 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RLAY alert in real time by email
    SC 13G/A 1 Relay_Th_Inc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING RELAY THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 75943R102 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO:75943R102 13G Page 2 of 5 Pages 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 4,673,384 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 4,903,578 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,903,578 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.98% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 75943R102 13G Page 3 of 5 Pages ITEM 1. (A) NAME OF ISSUER RELAY THERAPEUTICS INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE STATE STREET FINANCIAL CENTER 1 CONGRESS STREET, SUITE 1 BOSTON, MA 02114-2016 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 75943R102 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO:75943R102 13G Page 4 of 5 Pages ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS YES ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO:75943R102 13G Page 5 of 5 Pages ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS EUROPE LIMITED IA STATE STREET GLOBAL ADVISORS LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION.
    Get the next $RLAY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RLAY

    DatePrice TargetRatingAnalyst
    4/17/2025$4.00Equal Weight
    Wells Fargo
    9/10/2024$20.00Buy
    Goldman
    9/10/2024Outperform → Perform
    Oppenheimer
    9/10/2024$10.60 → $16.00Hold → Buy
    Jefferies
    5/10/2024$15.00Equal Weight → Overweight
    Barclays
    4/20/2023$12.50Underperform → Hold
    Jefferies
    4/19/2023$29.00Outperform → Strong Buy
    Raymond James
    4/13/2023$29.00Outperform
    Raymond James
    More analyst ratings

    $RLAY
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Relay Therapeutics Inc.

      SCHEDULE 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      7/29/25 2:22:24 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Relay Therapeutics Inc.

      8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

      6/11/25 4:12:42 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Relay Therapeutics Inc.

      8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

      6/6/25 5:00:55 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Catinazzo Thomas sold $74,000 worth of shares (20,081 units at $3.69), decreasing direct ownership by 6% to 335,295 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/30/25 4:54:19 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Rahmer Peter sold $62,947 worth of shares (17,083 units at $3.68), decreasing direct ownership by 4% to 377,998 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/30/25 4:54:35 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President, R&D Bergstrom Donald A sold $113,478 worth of shares (30,770 units at $3.69), decreasing direct ownership by 5% to 552,720 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/30/25 4:54:05 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Relay Therapeutics with a new price target

      Wells Fargo initiated coverage of Relay Therapeutics with a rating of Equal Weight and set a new price target of $4.00

      4/17/25 8:33:19 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman resumed coverage on Relay Therapeutics with a new price target

      Goldman resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $20.00

      9/10/24 7:59:04 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Relay Therapeutics from Outperform to Perform

      9/10/24 7:58:33 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment.

      6/20/25 9:21:00 AM ET
      $GRAL
      $IMRX
      $INTS
      $ONCY
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

      CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

      6/11/25 4:05:00 PM ET
      $BCAX
      $RLAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

      Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced updated interim clinical data for RLY-2608, the first known investigational allosteric, pan-

      6/2/25 7:00:13 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

      CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

      6/11/25 4:05:00 PM ET
      $BCAX
      $RLAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Section 32 Raises $740 Million Venture Fund

      SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

      11/4/21 8:14:00 AM ET
      $COIN
      $CRWD
      $EXAS
      $RLAY
      Finance: Consumer Services
      Finance
      Computer Software: Prepackaged Software
      Technology
    • Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

      Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform. This press release

      10/14/21 8:00:00 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Financials

    Live finance-specific insights

    See more
    • Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

      New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference call today, December 11, at 7am ET (6am CT) SAN ANTONIO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and expe

      12/11/24 6:00:00 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

      CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows:Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3C

      12/9/24 4:05:30 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

      9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia Data support planned initiation of 2L pivotal study in 2025 Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end Relay Therapeutics to host a conference call today, September 9, at 8:00 a.m. ET CAMBRIDGE,

      9/9/24 6:55:20 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.

      SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      11/14/24 1:22:38 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)

      SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      2/14/24 4:20:24 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Relay Therapeutics Inc.

      SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)

      2/14/24 10:03:03 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care